Crispr Therapeutics AG
General ticker "CRSP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.1B
Crispr Therapeutics AG does not follow the US Stock Market performance with the rate: -12.9%.
Estimated limits based on current volatility of 2.2%: low 39.41$, high 41.22$
Factors to consider:
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [36.14$, 79.71$]
- 2024-12-30 to 2025-12-30 estimated range: [37.89$, 80.45$]
Financial Metrics affecting the CRSP estimates:
- Negative: Non-GAAP EPS, $ of -1.96 <= 0.10
- Negative: Operating profit margin, % of -37.48 <= 1.03
- Negative: Operating cash flow per share per price, % of -4.77 <= 2.35
- Negative: negative Net income
- Negative: Inventory ratio change, % of 47.29 > 1.08
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
- Positive: Investing cash flow per share, $ of 4.73 > -0.12
Short-term CRSP quotes
Long-term CRSP plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $914.96MM | $1.20MM | $371.21MM |
| Operating Expenses | $541.43MM | $674.36MM | $593.74MM |
| Operating Income | $373.53MM | $-673.16MM | $-222.54MM |
| Non-Operating Income | $6.00MM | $22.66MM | $71.82MM |
| R&D Expense | $438.63MM | $461.64MM | $387.33MM |
| Income(Loss) | $379.53MM | $-650.50MM | $-150.72MM |
| Taxes | $1.87MM | $-0.33MM | $2.89MM |
| Profit(Loss) | $377.66MM | $-650.17MM | $-153.61MM |
| Stockholders Equity | $2,399.46MM | $1,875.48MM | $1,882.80MM |
| Inventory | $0.00MM | $11.20MM | $0.00MM |
| Assets | $2,751.88MM | $2,243.06MM | $2,229.57MM |
| Operating Cash Flow | $538.97MM | $-495.74MM | $-260.38MM |
| Capital expenditure | $81.70MM | $37.19MM | $11.97MM |
| Investing Cash Flow | $-1,035.43MM | $-258.65MM | $374.65MM |
| Financing Cash Flow | $250.94MM | $38.59MM | $62.66MM |
| Earnings Per Share* | $4.97 | $-8.36 | $-1.94 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.